Immune checkpoint blockade in locally advanced rectal cancer with deficient DNA mismatch repair: retrospective multicenter experience
Neoadjuvant ICI therapy for dMMR LARC produced cCRs in at least half of patients. These real-world data support the feasibility of nonoperative management, but the observed heterogeneity in clinical response highlights the need to optimize patient selection and monitoring strategies.
Authors
- N.R. Foster
- F.A. Sinicrope
- M. Singh
- P. Shah
- J.H. Strickler
- A. Gupta
- M.J. Overman
- K. Bonneau
- K.O. Steinert
- A. Saeed
- A. Opneja
- O.E. Emiloju
Institutions
- Mayo Clinic (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Pittsburgh (US)
- Mayo Clinic in Arizona (US)
- Duke Medical Center (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-12-31
- DOI
- https://doi.org/10.1016/j.esmoop.2025.106022
- Citations
- 1
- Primary Topic
- Genetic factors in colorectal cancer
- Type
- article
- Field-Weighted Citation Impact
- 1.47